Brought to you by:
Venous VQI celebrates decade milestone
At the recent VEITHsymposium (Nov. 19–23) in New York City, Marc Passman, MD, reflected on the achievements of the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) venous arm, in collaboration with the American Venous Forum (AVF), since its…
In search of the ‘holy grail’: New analysis brings aneurysm rupture prediction closer
A rupture prediction-based algorithm is set to enhance patient selection for abdominal aortic aneurysm (AAA) repair. This is according to Randy Moore, MD, a vascular surgeon at the University of Calgary in Calgary, Canada, who, at the 2024 VEITHsymposium (Nov.…
Endothermal ablation significantly outperforms surgery for varicose veins in long-term randomized trial
Ten-year data from the randomized HELP trial show that, while both endothermal ablation and conventional surgery are effective treatments for great saphenous varicose veins at 10 years, the former was associated with superior clinical and quality-of-life (QoL) outcomes. These findings…
CPVI course: Learning the latest intricate skills and techniques to treat complex PAD
Vascular Specialist attended the SVS Complex Peripheral Vascular Interventions (CPVI) Skills Course and spoke with participants about the hands-on learning experience designed for vascular surgeons and specialists at all stages of their careers. Over two days (Sept. 28–29), participants learned…
BIO-OSCAR SOC trial examines standard of care in PAD treatment
Biotronik today announced that it has concluded the BIO-OSCAR SOC study evaluating the baseline against which to measure the Oscar multifunctional catheter in treating complex peripheral arterial disease (PAD). The outcomes were presented at the Paris Vascular Insights (PVI) course 2024…
Applications open for 2025 James S.T. Yao Resident Research Award
The SVS Foundation is accepting applications for the 2025 James S.T. Yao Resident Research Award, which supports emerging medical professionals researching vascular disease biology and innovative translational therapies. The application deadline is Jan. 8, 2025. The recipient will present their…
Microbot Medical announces FDA submission for commercialization of Liberty endovascular robotic system
Microbot Medical recently announced that it has submitted a 510(k) premarket notification to the Food and Drug Administration (FDA) for its Liberty endovascular robotic system. A press release details that Liberty is the world’s first single-use, fully disposable robotic system…
Artivion granted FDA humanitarian device exemption for the AMDS hybrid prosthesis
Artivion recently announced that the Food and Drug Administration (FDA) has granted a humanitarian device exemption (HDE) for use of the AMDS hybrid prosthesis (formerly known as the Ascyrus Medical dissection stent) in acute DeBakey type I dissections in the…
First patient enrolled in InspireMD’s CGUARDIANS II pivotal study
InspireMD today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime carotid stent system in patients undergoing carotid artery stenting (CAS) via the transcarotid artery revascularisation (TCAR) approach. The patient was…
Innovation in vascular surgery: Balancing progress with patient safety
A debate at this year’s European Society for Vascular Surgery (ESVS 2024) annual meeting (Sept. 24–27) in Kraków, Poland, centered on innovation in vascular surgery, with experts considering whether it will “change everything.” While Matt Thompson, MBBS, chief executive officer…